Education
About Us
Working with TipRanks
Follow Us
Lumos Diagnostics Holdings Ltd. (AU:LDX)
ASX:LDX
Earnings Data
Report Date
Aug 25, 2026After Close (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
―Last Year’s EPS
>-0.01Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call was broadly positive: management secured a material exclusive U.S. distribution agreement (USD 317M minimum), completed and submitted the CLIA waiver study while expressing near-term optimism about approval, achieved strong product revenue growth and high gross margins, and materially improved cash flow and adjusted EBITDA versus prior years. Key risks remain including an outstanding CLIA waiver approval (which drives the commercial ramp), continued adjusted EBITDA losses, declines in IP/services revenue timing, and the need for incremental manufacturing capacity and near-term financing actions. Overall, the highlights (large distribution deal, reimbursement, margin improvement, improved cash flow, nondilutive funding and product momentum) outweigh the lowlights tied mainly to timing, conditionality of the waiver, and continued operating losses.Company Guidance
Secured Major U.S. Distribution Agreement (PHASE)
Signed a 6-year exclusive U.S. distribution agreement for FebriDx with PHASE Scientific that guarantees a minimum of USD 317 million in sales to Lumos over the term; PHASE also paid a USD 1.0 million exclusivity fee recognized in H1 revenue.
CLIA Waiver Study Completed and Submitted
Completed the CLIA waiver study in August and submitted to the U.S. FDA; management is optimistic a CLIA waiver grant will be announced imminently (targeted for March), which would materially expand addressable market and in-office use.
Reimbursement Secured
Secured Medicare/Medicaid reimbursement set by CMS at USD 41.38 per test with seven MACs agreeing to pay full reimbursement, improving the economics and adoption potential for FebriDx in physician offices.
Revenue and Product Revenue Growth
Reported first half revenue of USD 6.1 million; product revenue was USD 1.7 million vs USD 0.8 million in prior corresponding period, representing approximately a +112.5% increase year-over-year (driven largely by FebriDx).
Strong Gross Profit and Margin Improvement
Gross profit of USD 4.2 million and a gross margin of 68%, up 1 percentage point on the prior corresponding period and up 13 percentage points versus two years ago; FebriDx product margin indicated north of 60%.
Improved Cash Flow and Nondilutive Funding
Operating cash flow turned positive at USD 0.1 million in H1 versus an outflow of USD 6.8 million in the prior corresponding period; received USD 2.8 million in BARDA funding during H1 and secured ~USD 6.2 million to fund the pediatric trial. Management emphasized nondilutive financing actions (BARDA, IP arrangements, sale-leaseback, investor loan facility).
Reduction in Losses vs Prior Years
Adjusted EBITDA loss improved to USD 1.4 million in H1 (slightly worse than the immediate prior period but a significant improvement from FY24 H1 loss of USD 4.2 million), indicating progress toward profitability.
Services Business Performing and Backfilled Revenue
Services revenue of USD 4.4 million with ongoing project work (~14 projects recently), cash-flow positive services segment and new contract wins (e.g., Aptatek) that help offset reduced IP revenue recognition.
Pediatric Study Funding and Label Expansion
Secured funding (~USD 6.2 million) to run a pediatric trial to extend FebriDx label to ages 2–12; trial expected to complete by end of the calendar year and expand market by an estimated ~20%.
Lumos Diagnostics Holdings Ltd. (AU:LDX) Earnings, Revenues Date & History
AU:LDX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AU:LDX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | AU$0.26 | AU$0.28 | +7.84% |
Aug 27, 2025 | AU$0.13 | AU$0.14 | +7.69% |
Feb 26, 2025 | AU$0.03 | AU$0.03 | 0.00% |
Feb 27, 2024 | AU$0.07 | AU$0.07 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Lumos Diagnostics Holdings Ltd. (AU:LDX) report earnings?
Lumos Diagnostics Holdings Ltd. (AU:LDX) is schdueled to report earning on Aug 25, 2026, After Close (Confirmed).
What is Lumos Diagnostics Holdings Ltd. (AU:LDX) earnings time?
Lumos Diagnostics Holdings Ltd. (AU:LDX) earnings time is at Aug 25, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Lumos Diagnostics Holdings Ltd. stock?
The P/E ratio of Lumos Diagnostics Holdings Ltd. is N/A.
What is AU:LDX EPS forecast?
Currently, no data Available